Seagen Inc.
SGENDelisted Dec 14, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001060736
Seagen Inc. was delisted on Dec 14, 2023; its insiders filed their last Form 4 on Dec 18, 2023; 614 institutions reported holding it in 13F filings for Q3 2023, worth $36.3B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:17 PM ET
Revenue flow, FY2022
Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2022: $610.3M (31.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 15, 2023 | Feb 9, 2022 | Feb 11, 2021 | Feb 6, 2020 | Feb 7, 2019 |
| Revenue | $1.96B | $1.57B | $2.18B | $916.7M | $654.7M |
| Cost of revenue | $410.1M | $311.6M | $217.7M | – | – |
| Research and development | $1.34B | $1.23B | $827.1M | $719.4M | $565.3M |
| Selling, general and administrative | $821.0M | $716.2M | $533.8M | $373.9M | $261.1M |
| Operating income | -$613.0M | -$682.1M | $596.9M | -$220.5M | -$260.0M |
| Income tax | $7.99M | -$1.23M | $2.03M | $0 | -$23.7M |
| Net income | -$610.3M | -$674.5M | $613.7M | -$158.7M | -$222.7M |
| EPS, basic | $-3.30 | $-3.70 | $3.51 | – | – |
| EPS, diluted | $-3.30 | $-3.70 | $3.37 | – | – |
| Weighted shares, basic | 184.7M | 182.0M | 174.8M | – | – |
| Weighted shares, diluted | 184.7M | 182.0M | 182.3M | – | – |
| Margins and growth | |||||
| Operating margin | -31.2% | -43.3% | 27.4% | -24.1% | -39.7% |
| Net margin | -31.1% | -42.8% | 28.2% | -17.3% | -34.0% |
| Revenue growth, year over year | +24.6% | −27.6% | +137.3% | +40.0% | +35.8% |
| Net income growth, year over year | – | −209.9% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 15, 2023 | Feb 9, 2022 | Feb 11, 2021 | Feb 6, 2020 | Feb 7, 2019 |
| Cash and equivalents | $319.9M | $424.8M | $558.4M | $274.6M | $78.2M |
| Accounts receivable | $501.9M | $389.3M | $325.0M | $236.0M | $146.3M |
| Inventory | $427.2M | $200.7M | $116.1M | $85.9M | $53.2M |
| Total current assets | $2.80B | $2.87B | $3.06B | $1.18B | $653.6M |
| Property, plant and equipment | $248.2M | $210.1M | $196.7M | $155.5M | $103.8M |
| Goodwill | $274.7M | $274.7M | $274.7M | $274.7M | $274.7M |
| Intangible assets | $237.5M | $260.6M | $283.7M | – | $40.0K |
| Total assets | $3.67B | $3.72B | $4.00B | $2.21B | $1.50B |
| Accounts payable | $207.9M | $114.8M | $78.1M | $52.3M | $44.2M |
| Total current liabilities | $818.4M | $568.9M | $388.1M | $259.4M | $225.1M |
| Shareholders' equity | $2.80B | $3.07B | $3.49B | $1.88B | $1.27B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 15, 2023 | Feb 9, 2022 | Feb 11, 2021 | Feb 6, 2020 | Feb 7, 2019 |
| Operating cash flow | -$453.8M | -$499.0M | $856.6M | -$163.7M | -$203.5M |
| Capital expenditures | $77.3M | $52.3M | $82.4M | $70.8M | $21.2M |
| Free cash flow | -$531.1M | -$551.3M | $774.2M | -$234.5M | -$224.8M |
| Depreciation and amortization | $46.7M | $42.9M | $36.0M | $23.8M | $26.0M |
| Stock-based compensation | $221.3M | $173.1M | $147.2M | $127.3M | $78.9M |
| Investing cash flow | $228.2M | $288.9M | -$1.42B | -$277.7M | -$592.6M |
| Financing cash flow | $125.4M | $77.8M | $846.1M | $637.8M | $713.4M |
| Net change in cash | -$101.3M | -$133.6M | $283.9M | $196.4M | -$82.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 11.3% | 11.0% | 6.8% | 13.9% | 12.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 27, 2023 | 188.7M | +1.6% | SEC |
| Jul 28, 2023 | 187.7M | +1.8% | SEC |
| Apr 24, 2023 | 187.5M | +1.9% | SEC |
| Feb 10, 2023 | 186.8M | +1.7% | SEC |
| Oct 24, 2022 | 185.7M | +1.5% | SEC |
| Jul 25, 2022 | 184.4M | +1.4% | SEC |
| Apr 25, 2022 | 184.1M | +1.4% | SEC |
| Feb 4, 2022 | 183.6M | +1.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.